Is Hemant Surgical overvalued or undervalued?

As of 18 November 2025, the valuation grade for Hemant Surgical has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 45.47, an EV to EBITDA of 38.49, and a Price to Book Value of 3.28. In comparison to peers, Max Healthcare has a significantly higher PE ratio of 77.03, while Apollo Hospitals is at 63.51, indicating that Hemant Surgical's valuation remains elevated relative to its competitors.
Despite a strong year-to-date return of 124.64% compared to the Sensex's 8.36%, the high valuation ratios suggest that the stock is not justified at its current price of 283.50. The company's ROCE of 8.31% and ROE of 7.22% further indicate that while it has performed well, the market may be pricing in growth that is not fully supported by its financial metrics.